ASND · Ascendis Pharma A/S
Price
Snapshot
50 fields · last close| Market Cap | $14.21B |
| P/E | 17.03 |
| Float | 63.84M |
| Beta | 0.39 |
| Volatility | 9.6% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 75.8 |
| Price | 227.87 |
| Change | +0.00% |
| Prev Close | 227.87 |
| Open | 227.63 |
| Day Low | 225.20 |
| Day High | 229.02 |
| Avg Vol | 1 |
| Avg $ Vol | $183.2M |
| 52W High | 282.15 |
| 52W Low | 186.05 |
| 52W Pos | 43.5% |
| From High | −19.24% |
| From Low | +22.48% |
| Max DD 1Y | −19.50% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −6.03% |
| SMA 50 | −8.37% |
| SMA 200 | −3.27% |
| RSI (14) | 37.8 |
| Vol 30D | 45.8% |
| Vol 90D | 40.7% |
| 1Y Range | 186–282 |
| Daily bars | 900 |
| Perf Week | +1.01% |
| Perf Month | −14.75% |
| Perf Quarter | −14.95% |
| Perf Half Y | −0.60% |
| Perf Year | +11.64% |
| Perf YTD | +6.84% |
| Prev Day | +0.00% |
| Clavix | B+ |
| Debt / Eq | 1.93 |
| Curr Ratio | 1.04 |
| Int Cover | 0.3× |
| FCF Margin | 44.2% |
| Rev Growth | +114.7% |
| Profit | Unprofitable |
| Leverage | High |
| Sector rank | 11 / 35 |
Clavix risk grade
regraded every trading dayASND grades B+, 75.8 of 100. Steadiest on Macro Resilience (69), most exposed on Price Stability (56, mixed). 3 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 11 of 35 in Biotechnology by Clavix score.
How rough the ride is
| ASND | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.39 | 0.50 |
| Volatilityannualized | 9.6% | 14.4% |
| Max drawdown, past yearworst peak-to-trough fall | −19.5% | — |
| Typical daily movemedian absolute daily change | 1.21% | — |
| Days beyond ±3%of the last 252 sessions | 52 (21%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ASND | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.39 | 0.50 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 53% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ASND | |
|---|---|
| 1 week | +1.0% |
| 1 month | −14.8% |
| Year to date | +6.8% |
| 1 year | +11.6% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ASND | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 13 Aug |
| Average score0 most bearish, 100 most bullish | 63 |
| Bullish · bearisharticles above 60 · below 40 | 21 · 5 |
| Directionarticles whose tone is improving vs worsening | 21 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| ASND | |
|---|---|
| Revenue growthyear over year | +114.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openWall Street Zen lowered its rating on Ascendis Pharma from 'buy' to 'hold' in a research note. No company-specific news or financial details were provided.
Ascendis Pharma's board authorized buying back up to $400 million of its shares on September 14, backed by a strong quarter where product revenue jumped 105% to €315 million, driven by YORVIPATH sales now spanning 35+ countries, and cash on hand of €812 million. The buyback is discretionary and the company is not obligated to repurchase any specific amount.
Ascendis Pharma has regained full rights to its TransCon technology-based products for metabolic and cardiovascular diseases after ending its collaboration with Novo Nordisk. The company plans to advance its own programs in obesity and type 2 diabetes, including a planned once-monthly version of semaglutide (a GLP-1 drug currently sold weekly as Ozempic and Wegovy).
Ascendis Pharma announced it will regain exclusive rights to develop, manufacture, and sell its TransCon metabolic and cardiovascular drug candidates after ending its partnership with Novo Nordisk. The regained assets include TransCon Semaglutide, an experimental once-monthly version of semaglutide (a drug currently sold as Ozempic and Wegovy) being studied for obesity and type 2 diabetes.
Ascendis Pharma is regaining full independence after Novo returned the rights to TransCon, adding to earlier partner exits and pipeline setbacks. Despite those negatives, the company's three approved drugs, Skytrofa, Yorvipath, and Yuviwel, are growing, Yorvipath sales are projected to top $1.1 billion this year, the Yuviwel U.S. launch is going well, and a favorable BioMarin settlement gives the company freedom to operate.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| EXEL | Exelixis Inc | B+ | $14.47B | 16.81 | 0.44 | Compare |
| NBIX | Neurocrine Biosciences Inc | B+ | $14.55B | 20.63 | 0.34 | Compare |
| BBIO | BridgeBio Pharma Inc | B | $13.15B | — | 0.95 | Compare |
| HALO | Halozyme Therapeutics Inc | B | $12.47B | 30.15 | 0.94 | Compare |
| TWST | Twist Bioscience Corp | D+ | $12.42B | — | 2.17 | Compare |
| MDGL | Madrigal Pharmaceuticals Inc | B | $11.54B | — | -1.08 | Compare |
| KRYS | Krystal Biotech Inc | B | $9.54B | 39.51 | 0.65 | Compare |
| CYTK | Cytokinetics Inc | B | $9.12B | — | 0.42 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.